

Methods: In our Navigate Program, we have developed strategies based on literature and experience that enables the person/family to be part of the decision-making process, which at times presents dilemmas and risks but also promotes the potential for growth and transformation.

Results: How do we talk about the medication issue? Who can continue without medication or with very low dosage? How can we taper antipsychotic treatment?

Conclusions: Are we willing to take the risk?

Disclosure: No significant relationships.

Keywords: Navigate; long term antipsychotic treatment; shared decision making; first psychosis

EPV1431

Gender differences in clinical and psychosocial features in a large sample of Italian patients with schizophrenia

P. Bucci^{1*}, S. Galderisi¹, A. Rossi², P. Rocca³, A. Bertolino⁴, G.M. Giordano¹, A. Mucci¹ and M. Maj¹

¹University of Campania, Department Of Psychiatry, Naples, Italy; ²University of L'Aquila, Department Of Biotechnological And Applied Clinicalsciences, Section Of Psychiatry, L'Aquila, Italy; ³University of Turin, Department Of Neuroscience, Section Of Psychiatry, Turin, Italy and ⁴University of Bari Aldo Moro, Basic Medical Science, Neuroscience And Sense Organs, Bari, Italy
*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2057

Introduction: An extensive literature regarding gender differences relevant to several aspects of schizophrenia is nowadays available. It includes some robust findings as well as some inconsistencies. The identification of gender differences and the understanding of their explanations may help to clarify the underlying etiopathogenetic mechanisms of specific aspects of the disorder.

Objectives: The present study aimed at investigating gender differences on premorbid, clinical, cognitive and outcome indices, as well as their impact on recovery, in a large sample of patients with schizophrenia recruited within the multicenter study of the Italian Network for Research on Psychoses.

Methods: State-of-the-art instruments were used to assess the investigated domains. Group comparisons between male and female patients were performed on all considered indices. The associations of premorbid, clinical and cognitive indices with recovery in the two patient groups were investigated by means of multiple regressions.

Results: Males with respect to females had a worse premorbid adjustment – limited to the academic dimension – an earlier age of onset, a higher frequency of history of substance and alcohol abuse, more severe negative symptoms (both avolition and expressive deficit), positive symptoms and impairment of social cognition. No gender difference was observed in neurocognition nor in the rates of recovery.

Conclusions: Although males showed some disadvantages in the clinical picture, this was not translated into a worse outcome. This finding may be related to the complex interplay of several factors acting as predictors or mediators of outcome.

Disclosure: No significant relationships.

Keywords: Gender differences; Recovery; schizophrenia; sex differences

EPV1432

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia

B. Marpepa^{1*}, C. Appignanesi², L. Orsolini², U. Volpe¹ and V. Salvi³

¹Politechnic University of Marche, Department Of Neuroscience/dimsc, Ancona, Italy; ²Polytechnic University of Marche, Department Of Clinical Neurosciences/dimsc, School Of Medicine, Unit Of Psychiatry, Ancona, Italy and ³Università Politecnica delle Marche, Unit Of Clinical Psychiatry, Department Of Clinical Neurosciences/dimsc, Ancona, Italy

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2058

Introduction: Aripiprazole LAI is approved for the treatment of schizophrenia in adults. Recently, Europe and Canada approved the use of the two-injection start (TIS) regimen: two separate injections of 400 mg long-acting aripiprazole along with a single 20 mg dose of oral aripiprazole. Aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13-17 year-old adolescents with schizophrenia by the EMA. However, the LAI formulation still remains off-label in adolescents.

Objectives: To demonstrate the efficacy and safety of the TIS regimen of aripiprazole LAI formulation in a 16 year-old adolescent with schizophrenia.

Methods: We evaluated the symptoms of schizophrenia and general severity by means of the PANSS and CGI scales. The scales were administered at hospital admission, after 3 weeks, 5 weeks, and at 4-weeks follow-up.

Results: At the admission the patient PANSS total score was 136, the CGI score of 7. Aripiprazole was started and up-titrated to 30 mg/day. After 3 weeks, the positive symptoms were significantly reduced; due to the persistence of negative symptoms, clozapine 100 mg/day was added. At week 5 the PANSS total score decreased to 81. Due to poor insight we proposed aripiprazole LAI with the two-injection start. One month later, global functioning and illness insight improved; PANSS score was 43, CGI score 2. There was no evidence of akathisia or other side effects.

Conclusions: Aripiprazole LAI showed good efficacy and tolerability in an adolescent with schizophrenia. The two-injection start regimen was a safe and viable option.

Disclosure: No significant relationships.

Keywords: schizophrenia; lai two-injection; Psychofarmacology; Psychosis

EPV1433

Are conspiracy theorists psychotic? A comparison between conspiracy theories and paranoid delusions

W. Veling¹, B. Sizoo², J. Van Buuren³, C. Van Den Berg², W. Sewbalak⁴, G. Pijnenborg^{5,6}, N. Boonstra⁷, S. Castelein^{8,9*} and L. Van Der Meer^{6,10}

¹University Medical Center Groningen, University Center For Psychiatry, Groningen, Netherlands; ²Dutch National Police, National Unit, Driebergen, Netherlands; ³Leiden University, Institute Of Security And Global Affairs, Den Haag, Netherlands; ⁴GGz Delfland, Poli Schiedam, Schiedam, Netherlands; ⁵GGZ Drenthe, Department Of

Psychotic Disorders, Assen, Netherlands; ⁶University of Groningen, Clinical And Developmental Neuropsychology, Groningen, Netherlands; ⁷University of Applied Sciences, Care And Innovation, Leeuwarden, Netherlands; ⁸Lentis Psychiatric Institute, Lentis Research, Groningen, Netherlands; ⁹University of Groningen, Experimental Psychopathology And Clinical Psychology, Groningen, Netherlands and ¹⁰Lentis Psychiatric Institute, Department Of Rehabilitation, Zuidlaren, Netherlands

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2059

Introduction: Conspiracy theories are popular during the COVID-19 pandemic. Conspiratorial thinking is characterised by the strong conviction that a certain situation that one sees as unjust is the result of a deliberate conspiracy of a group of people with bad intentions. Conspiratorial thinking appears to have many similarities with paranoid delusions.

Objectives: To explore the nature, consequences, and social-psychological dimensions of conspiratorial thinking, and describe similarities and differences with paranoid delusions.

Methods: Critically assessing relevant literature about conspiratorial thinking and paranoid delusions.

Results: Conspiratorial thinking meets epistemic, existential, and social needs. It provides clarity in uncertain times and connection with an in-group of like-minded people. Both conspiratorial thinking and paranoid delusions involve an unjust, persistent, and sometimes bizarre conviction. Unlike conspiracy theorists, people with a paranoid delusion are almost always the only target of the presumed conspiracy, and they usually stand alone in their conviction. Furthermore, conspiracy theories are not based as much on unusual experiences of their inner self, reality, or interpersonal contacts.

Conclusions: Conspiratorial thinking is common in uncertain circumstances. It gives grip, certainty, moral superiority and social support. Extreme conspiratorial thinking seems to fit current psychiatric definitions of paranoid delusions, but there are also important differences. To make a distinction with regard to conspiratorial thinking, deepening of conventional definitions of delusions is required. Instead of the strong focus on the erroneous content of delusions, more attention should be given to the underlying idiosyncratic, changed way of experiencing reality.

Disclosure: No significant relationships.

Keywords: conspiracy theories; paranoid delusions; Covid-19

EPV1434

Quality of life of patients with schizophrenia

A. Guerhazi*, N. Smaoui, D. Jardak, S. Omri, R. Feki, I. Gassara, M. Maalej, N. Charfi, L. Zouari, J. Ben Thabet and M. Maalej

Hedi Chaker University Hospital, Sfax, Tunisia, Department Of Psychiatry C, Sfax, Tunisia

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2060

Introduction: Schizophrenia (SCZ) is considered one of the most disabling mental illnesses with significant family, social and occupational repercussions resulting in impaired quality of life (QOL).

Objectives: To assess the QOL of patients with SCZ or schizoaffective disorder (SAD) and to analyze the sociodemographic and clinical factors associated with its alteration.

Methods: This was a cross-sectional, descriptive and analytical study, which began in December 2019, conducted with 60 subjects

followed for SCZ or SAD, at the psychiatry outpatient unit of the Hedi Chaker University Hospital in Sfax (Tunisia). General, clinical and therapeutic data were collected using a pre-established questionnaire. QOL was assessed with the «36 item Short-Form Health Survey» (SF-36).

Results: Patients enrolled had SCZ in 78.2% and SAD in 21.8% of cases. The mean age was 47.2 years and the sex ratio M/F was 4.5. They were single in 63.7% of cases and unemployed in 61.8%. Psychiatric family history, the presence of personal somatic illnesses and tobacco use were found in 43.6%, 61.8% and 67.3% of cases, respectively. The average QOL score was 57.7, the average physical health score was 61.1, and the average mental health score was 54.3. Female sex ($p=0.02$), being single ($p=0.039$), lack of work activity ($p=0.00$), tobacco use ($p=0.05$), and presence of medical history ($p=0.034$) were statistically correlated with impaired QOL.

Conclusions: QOL in SCZ and SAD is impaired. This result encourages us to conceive of the patient in his whole life and not only from the point of view of the disease.

Disclosure: No significant relationships.

Keywords: Quality of Life; schizophrenia; 36 item Short-Form Health Survey; Schizoaffective disorder

EPV1435

Schizophrenia with obsessive-compulsive suicidal images

V.-M. Vasadi^{1*}, O. Capatina² and M. Fadgyas Stanculete²

¹Cluj County Emergency Hospital, 2nd Psychiatry Department, Cluj-Napoca, Romania and ²Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Department Of Neurosciences - Psychiatry, Cluj-Napoca, Romania

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.2061

Introduction: Background A 19-year old patient with a history of traumatic childhood events presents herself for suicidal behavior driven by complex auditory hallucinations, self-mutilating behavior, and obsessive-compulsive suicidal images that depicted the patient lying dead on the floor with both wrists cut open. Prior to hospitalization, over the past 10 months, the patient exhibited symptoms of low mood, anhedonia, and an overall decline in school performance which led to a diagnosis of MDD with psychotic symptoms, but treatment with Duloxetine 60mg and Olanzapine 10mg proved to be inefficient.

Objectives: Case Presentation Upon admission the patient's mimic and behavior did not support the described sadness, she presented a circumstantial discourse with frequent thought blockages and delusions. Associated the patient also described hypervigilance and avoidance behavior towards men, flashbacks, vivid nightmares, and obsessive-compulsive self-mutilating impulses and images.

Methods: Initially, treatment was started with Olanzapine 20mg, which was augmented two months later with Sertraline 50mg and Bromazepam 3mg. This treatment led to an incomplete resolution of the obsessive symptoms, which led to the increase of Sertraline at 100mg, but at her 1-month check-up evaluation, she presented increased suicidal ideation and daily obsessive-compulsive images.

Results: The patient was lastly diagnosed with schizophrenia, and due to the persistence of the suicidal ideations and delusions and the obsessive-compulsive symptoms, the treatment plan was revised.

Conclusions: Improvement of symptoms appeared under treatment with 300mg Clozapine and 50mg Fluvoxamine. In total the patient needed 98 days of hospitalization and lasting remission of symptoms appeared only under treatment with Clozapine and Fluvoxamine.